Quick Comparison: Tirzepatide vs Retatrutide
| Factor | Tirzepatide | Retatrutide |
|---|---|---|
| Mechanism | Dual GLP-1 + GIP agonist | Triple GLP-1 + GIP + Glucagon agonist |
| Developer | Eli Lilly | Eli Lilly |
| FDA Status | ✓ Approved (Zepbound / Mounjaro) | ✗ Phase 3, no NDA filed yet |
| Available Now? | ✓ Yes — brand + compounded | ✗ No — not until late 2027 earliest |
| Peak trial weight loss | 22.5% at 72 weeks (SURMOUNT-1, Phase 3) | 28.3% at 80 weeks, up to 30.3% at 104 weeks (TRIUMPH-1, Phase 3) |
| Trial quality | Large Phase 3 RCT — definitive data | Now Phase 3 (TRIUMPH-1, -4; TRANSCEND-T2D-1 reported) |
| Notable safety signal | Established profile; mild heart rate increase | Dysesthesia (up to 12.5% at 12mg); higher discontinuation rates |
| Compounded access | ✓ Yes — Luma Health $297/mo flat | ✗ Not legally available (investigational) |
| NDA filing timeline | N/A (already approved) | Estimated Q4 2026 – Q1 2027 |
| Realistic FDA approval | Already approved | Late 2027 at earliest |
The Mechanisms: What Each Receptor Does
To understand what separates tirzepatide from retatrutide, you need to understand the three hormone receptors involved and what each contributes to weight regulation. This is where the "dual vs triple agonist" distinction becomes clinically meaningful rather than just a marketing label.
GLP-1 Receptor
- Appetite suppression via hypothalamic signaling
- Slows gastric emptying (prolongs satiety)
- Stimulates glucose-dependent insulin release
- Suppresses post-meal glucagon
- Primary driver of GI side effects (nausea, etc.)
GIP Receptor
- Enhances insulin sensitivity in peripheral tissues
- Direct signaling in adipose tissue (fat cells)
- Synergistic appetite suppression with GLP-1
- May buffer GLP-1's GI side effects
- Key reason tirzepatide outperforms semaglutide
Glucagon Receptor
- Activates brown adipose thermogenesis (burns more calories)
- Increases hepatic fat oxidation (liver burns stored fat)
- Raises resting metabolic rate
- Associated with dysesthesia signal in Phase 3
- Blood sugar risk offset by concurrent GLP-1/GIP
The addition of glucagon receptor agonism is retatrutide's theoretical advantage: while GLP-1 and GIP primarily reduce caloric intake through appetite suppression, glucagon agonism raises the body's baseline energy expenditure. It adds an energy output component to the appetite input reduction that tirzepatide already provides — effectively adding a metabolic accelerator alongside the appetite brake.
The blood sugar concern with glucagon activation (glucagon normally raises blood glucose) is mitigated in practice by the concurrent GLP-1 and GIP activation, which robustly stimulate insulin secretion. Retatrutide's Phase 3 program, including a dedicated type 2 diabetes trial (TRANSCEND-T2D-1), has not shown problematic hyperglycemia — the three hormonal effects appear to counterbalance at the relevant receptors.
Clinical Trial Results: The Data Now Includes Phase 3
Tirzepatide — SURMOUNT-1 (Phase 3, 2022)
N=2,539 adults without T2D. Duration: 72 weeks.
Retatrutide — TRIUMPH-1 (Phase 3, pivotal, May 2026)
N=2,339 adults with obesity. Duration: up to 104 weeks. First pivotal Phase 3 obesity readout.
Side Effect Profiles: What's Different
Both drugs share the core GLP-1 side effect profile — nausea, GI symptoms, and injection site reactions that are most prominent during dose escalation. The Phase 3 data have clarified some retatrutide-specific signals beyond the heart rate effect first noted in Phase 2.
Tirzepatide — Established Safety Profile
- Nausea: 18–35% (primarily during escalation)
- Diarrhea: 12–23%
- Vomiting: 8–13%
- Constipation: 7–15%
- Heart rate increase: ~2–3 bpm (mild)
- Rare: pancreatitis, gallbladder disease
- 5+ years of real-world safety data accumulating
Retatrutide — Now With Phase 3 Data
- Nausea, diarrhea, vomiting, constipation: similar or slightly higher rates
- Heart rate increase: more pronounced than tirzepatide
- Dysesthesia (abnormal skin sensation): up to 12.5% at the 12 mg dose in TRIUMPH-1
- Discontinuation rates: 4.1–11.3% across doses vs 4.9% placebo
- A urinary tract infection signal has been noted and is being monitored
- Full cardiovascular safety continues to be characterized across the remaining TRIUMPH readouts
The dysesthesia signal and elevated discontinuation rates at the highest dose are new information from the Phase 3 program that were not clearly visible in the smaller Phase 2 study. For patients considering retatrutide once available, this means the drug's tolerability profile — not just its efficacy — will be an important part of the eventual FDA review and prescribing decision.
Retatrutide's Approval Timeline: The Realistic View
Retatrutide FDA Approval Timeline (Updated)
Should You Wait for Retatrutide or Start Tirzepatide Now?
✓ Start Tirzepatide Now — Strong Arguments
- Treatment delay means ongoing health burden — cardiovascular, metabolic, joint, and psychological effects of obesity accumulate with each untreated year
- Tirzepatide produces 20–22.5% average weight loss — genuinely transformative by any historical standard for a medication
- Retatrutide remains at least 1–2 years from approval, even with strong Phase 3 data now in hand
- Tirzepatide has accumulating real-world safety data; retatrutide's dysesthesia signal and discontinuation rates are still being fully characterized
- If retatrutide is eventually approved and proves meaningfully superior for your specific case, switching is straightforward
- Compounded tirzepatide available now at $297/mo flat — no insurance required
⚠ Consider Waiting — Limited Scenarios
- You have already completed a full course of tirzepatide and achieved inadequate response — retatrutide's additional glucagon mechanism may address what tirzepatide's dual mechanism doesn't
- Your clinician has identified specific metabolic factors where glucagon receptor agonism may provide incremental benefit specific to your case
- You have no urgent metabolic health concerns and prefer to wait for a drug whose full safety profile (including the dysesthesia signal) is better characterized before committing
- You are closely monitoring the retatrutide TRIUMPH trial program or a future expanded-access pathway
For the vast majority of patients with obesity-related health concerns, the clinical evidence still favors starting an effective, available medication now rather than waiting at least one to two more years for a drug that, while now backed by strong Phase 3 data, is not yet approved and has an emerging safety profile that includes a new dysesthesia signal. Tirzepatide's 22.5% average weight loss is already among the highest ever documented for a pharmacological treatment prior to retatrutide's Phase 3 results, and it remains an excellent option today.
Available today.
$297/mo flat tirzepatide.
Compounded tirzepatide $297/month flat. VialsRX pharmacy (TX Board #35264). No contracts. Wasef Health, PC clinical oversight.
Start Tirzepatide Today →Frequently Asked Questions
Tirzepatide is a dual GLP-1/GIP receptor agonist FDA-approved for obesity (as Zepbound) and type 2 diabetes (as Mounjaro). It suppresses appetite through two hormone pathways and has demonstrated 22.5% average weight loss at 72 weeks in Phase 3 trials. Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist developed by Eli Lilly, now with three completed Phase 3 readouts but not yet FDA-approved. The additional glucagon receptor component is designed to increase energy expenditure, adding an energy-output mechanism to the appetite suppression tirzepatide already provides. In the pivotal TRIUMPH-1 Phase 3 trial, retatrutide produced 28.3% average weight loss at 80 weeks — a larger gap over tirzepatide than earlier Phase 2 estimates suggested.
Based on the pivotal Phase 3 TRIUMPH-1 trial (May 2026), retatrutide produced 28.3% average weight loss at 80 weeks (up to 30.3% at 104 weeks) compared to tirzepatide's 22.5% at 72 weeks in SURMOUNT-1. This is now Phase 3-to-Phase 3 data, addressing the earlier caveat that Phase 2 estimates might overstate the eventual result — if anything, the Phase 3 result was in line with or above the earlier Phase 2 signal. The trials still used different patient populations and durations, so some caution in direct comparison remains warranted, but the gap is better supported by evidence than it was previously.
As of July 2026, retatrutide remains in Phase 3 with no NDA filed. Based on the completed TRIUMPH-1 and TRIUMPH-4 readouts and the expected TRIUMPH-2 and TRIUMPH-3 results later in 2026, industry estimates place an NDA filing around Q4 2026 or Q1 2027. Under a standard ~10-month FDA review, the earliest realistic approval would be late 2027. No official timeline has been confirmed by Eli Lilly or the FDA — these are industry projections based on disclosed trial schedules.
Dysesthesia refers to an abnormal, often unpleasant sensation on the skin (such as tingling, burning, or crawling sensations) without an external cause. In the pivotal TRIUMPH-1 Phase 3 trial, this occurred in up to 12.5% of patients on the 12 mg retatrutide dose — a signal that was not clearly apparent in the earlier, smaller Phase 2 study. This has been accompanied by somewhat higher discontinuation rates at higher doses (4.1–11.3% depending on dose, vs. 4.9% on placebo). This will be an important part of FDA's eventual safety review and of the prescribing conversation once retatrutide reaches the market.
No. Compounded retatrutide is not legally available in the United States as of July 2026. Compounding of a prescription drug is only permitted by the FDA when that drug is FDA-approved and appears on the agency's shortage list. Retatrutide is not yet FDA-approved, so it cannot be legally compounded. This will only change after approval and commercial launch, and only if retatrutide subsequently encounters a supply shortage. At launch, retatrutide will be available only as a brand-name product.
Yes, for the vast majority of patients. Retatrutide is still at least one to two years from availability at minimum, even with its Phase 3 data now reported — every month of delayed treatment is another month with the health consequences of untreated obesity. Tirzepatide produces 22.5% average weight loss in Phase 3 trials, which remains genuinely transformative and among the most effective weight loss interventions available today. Retatrutide's now better-supported advantage (~6 percentage points based on Phase 3-to-Phase 3 comparison) is meaningful, but the drug is not yet approved, is not yet available at any price, and carries a safety profile — including the dysesthesia signal — that is still being fully characterized. If retatrutide is eventually approved and proves meaningfully superior for your specific case, transitioning to it at that time is straightforward.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed 35658024
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. PubMed 37366315
- Jastreboff AM, et al. TRIUMPH-4 Phase 3 Results (retatrutide, osteoarthritis population). N Engl J Med. December 2025.
- Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the Treatment of Obesity, Obstructive Sleep Apnea and Knee Osteoarthritis: Rationale and Design of the TRIUMPH Registrational Clinical Trials. Diabetes Obes Metab. 2026;28(1):83–93.
- Eli Lilly and Company. TRIUMPH Phase 3 Clinical Trial Program. ClinicalTrials.gov: NCT05929079 and related identifiers.
- FDA. Zepbound (tirzepatide) Prescribing Information. 2023. FDA.gov
- Rubino DM, et al. Effect of Continued Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414–1425. PubMed 33755728
- NIDDK. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov